Agilent Unveils AI-Powered Automation Suite at SLAS2026
Event summary
- Agilent will showcase next-generation automated lab solutions at SLAS2026 (Feb 7–11) in Boston, integrating AI, robotics, and advanced imaging.
- New ProteoAnalyzer Software Security Module targets compliance with 21 CFR Part 11 and Annex 11 for pharmaceutical labs.
- AI-driven CrossLab Connect platform introduces real-time performance analytics and predictive alerts for lab optimization.
- Preview of Cytation imaging family upgrade with enhanced optics and faster data acquisition for high-content imaging.
- Agilent partners with ABB Robotics, HighRes Biosolutions, Biosero, and Unite Labs for multi-vendor automated environments.
The big picture
Agilent’s push for AI-powered lab automation aligns with the broader industry shift toward digital transformation in life sciences. The company’s $6.95 billion revenue in fiscal 2025 underscores its scale, but its ability to differentiate through open connectivity and multi-vendor partnerships will be critical in maintaining market share. The focus on compliance-ready software highlights the growing importance of regulatory adherence in biopharmaceutical manufacturing.
What we're watching
- Market Adoption
- How quickly pharmaceutical and biopharmaceutical labs will integrate Agilent’s AI-driven automation tools into regulated workflows.
- Competitive Positioning
- Whether Agilent can sustain its leadership in lab automation amid increasing competition from robotics and software partners.
- Regulatory Compliance
- The pace at which Agilent’s ProteoAnalyzer Software Security Module will be adopted to meet global regulatory requirements.
Related topics